Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis
Diabetic Medicine · 2024
DOI: 10.1111/dme.15394 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetic Medicine, 2024. Verfasst von Shanice J Lewis und 8 weiteren Autor:innen. Beteiligte Einrichtung: Translational Health Sciences, Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Autoantibodies, Diabetes Mellitus, Type 2, Islets of Langerhans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus, Kinderkrankenpflege
Abstract (Originalsprache)
Aim
This study aimed to evaluate characteristics of autoimmunity in individuals who have a type 2 diagnosis and are relatives of children with type 1 diabetes.
Methods
Pre‐diagnosis samples (median 17 months before onset) from relatives who were later diagnosed with type 2 diabetes were measured for autoantibodies to glutamate decarboxylase 65 (GADA), islet antigen‐2 (IA‐2A), zinc transporter 8 (ZnT8A) and insulin (IAA) as well as the type 1 diabetes genetic risk score (GRS2). Associations between islet autoantibodies, insulin treatment and GRS2 were analysed using Fisher's exact and t ‐tests.
Results
Among 226 relatives (64% men; mean age at sampling 41 years; mean age 54 years at diagnosis), 32 (14%) were islet autoantibody‐positive for at least one autoantibody more than a decade before diagnosis. Approximately half of these ( n = 15) were treated with insulin. GADA‐positivity was higher in insulin‐treated relatives than in non‐insulin‐treated relatives (12/18 [67%] vs. 6/18 [33%], p < 0.001). IAA‐positivity was observed in 13/32 (41%) of relatives with autoantibodies. GRS2 scores were increased in autoantibody‐positive relatives ( p = 0.032), but there was no clear evidence for a difference according to treatment ( p = 0.072).
Conclusion
This study highlights the importance of measuring islet autoantibodies, including IAA, in relatives of people with type 1 diabetes to avoid misdiagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Translational Health Sciences, Diabetes and Metabolism, Bristol Medical School, University of Bristol, Bristol, UK.
- Institute of Biomedical and Clinical Science, Faculty of Health and Life Sciences, University of Exeter, Exeter, United Kingdom.
- Pacific Northwest Diabetes Research Institute, University of Washington, Seattle, Washington, USA.
ORCID-Profile: Shanice J Lewis, Claire L Williams, Georgina L Mortimer, Richard A Oram, William A Hagopian, Kathleen M Gillespie, Anna E Long
Zitieren
APA
Lewis, S. J., Williams, C. L., Mortimer, G. L., AWAF, BOX Study Group, Oram, R. A., Hagopian, W. A., Gillespie, K. M., & Long, A. E. (2024). Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis. Diabetic Medicine. https://doi.org/10.1111/dme.15394
Vancouver
Lewis SJ, Williams CL, Mortimer GL, AWAF, BOX Study Group, Oram RA, et al. Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis. Diabetic Medicine. 2024. doi:10.1111/dme.15394
BibTeX
@article{Lewis2024,
author = {Lewis, Shanice J and Williams, Claire L and Mortimer, Georgina L and AWAF, AWAF and BOX Study Group, BOX Study Group and Oram, Richard A and Hagopian, William A and Gillespie, Kathleen M and Long, Anna E},
title = {Islet autoantibody frequency in relatives of children with type 1 diabetes who have a type 2 diabetes diagnosis},
journal = {Diabetic Medicine},
year = {2024},
doi = {10.1111/dme.15394}
}
EUVIMED